Abstract
This open-label study investigated the strategy of switching patients who had gained excessive weight on olanzapine to quetiapine, with assessments of safety and continued efficacy as well as weight change. Patients who were psychiatrically stable on olanzapine but had gained >20% in weight and had body mass index >25 mg/kg(2) were switched to quetiapine over a 4-week period and followed for 6 weeks, the total study duration being 10 weeks. Assessments included weight change, antipsychotic efficacy using the Positive and Negative Symptom Syndrome Scale (PANSS), extrapyramidal adverse events using the Simpson-Angus Scale (SAS), and laboratory studies for metabolic measures. Of 16 enrolled patients, 12 completed the study. Mean weight loss was 2.25 kg (Cohen's d = 0.12; P = 0.03). There were no significant changes in PANSS total scores, SAS scores, or metabolic parameters. Switching patients to quetiapine, appears to be a viable strategy for managing olanzapine-induced weight gain as indicated by this 10-week open-label study. Prospective controlled trials of longer duration and larger number of subjects are needed.
References
Jun 11, 1998·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·S GuptaB Frank
Oct 8, 1999·The New England Journal of Medicine·E E CalleC W Heath
Nov 5, 1999·JAMA : the Journal of the American Medical Association·A MustW H Dietz
Apr 13, 2000·Archives of Internal Medicine·UNKNOWN National Task Force on the Prevention and Treatment of Obesity
May 16, 2000·The Journal of Clinical Psychiatry·G L Blackburn
Feb 24, 2001·Lancet·G J WangJ S Fowler
Mar 16, 2001·Expert Opinion on Pharmacotherapy·S Kasper, F Müller-Spahn
Mar 16, 2001·Expert Opinion on Pharmacotherapy·P S Masand
May 31, 2001·The Journal of Clinical Psychiatry·B R BassonG D Tollefson
Jun 13, 2001·Pharmacotherapy·R M CarnahanP J Perry
Oct 5, 2001·Expert Opinion on Pharmacotherapy·P E KeckL M Arnold
Oct 13, 2001·European Child & Adolescent Psychiatry·K M Haapasalo-Pesu, S Saarijärvi
Feb 9, 2002·Clinical Therapeutics·Glen L StimmelVivian Lee
May 15, 2002·Journal of Clinical Psychopharmacology·Pál CzoborJeffrey A Lieberman
Jun 28, 2002·Lancet·Gavin P ReynoldsXiao-Bin Zhang
Aug 15, 2002·International Clinical Psychopharmacology·M AratoUNKNOWN ZEUS Study Group
Dec 31, 2002·Psychoneuroendocrinology·H Nasrallah
Jul 2, 2005·Journal of Psychiatric Practice·P S Masand, S Gupta
Jul 2, 2005·Journal of Psychiatric Practice·P J Weiden
Citations
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Feb 4, 2009·Current Psychiatry Reports·John O BrooksOlya Krasnykh
Jul 4, 2013·CNS Drugs·Anja CeroveckiMichael Riedel
Sep 13, 2007·Molecular Psychiatry·H A Nasrallah
May 19, 2007·Journal of the American Pharmacists Association : JAPhA·L Douglas RiedFarzad Rahnavard
Aug 18, 2006·Journal of the American Pharmacists Association : JAPhA·L Douglas RiedLarry M Lopez
Oct 1, 2009·Asian Journal of Psychiatry·Ranita BasuK N Roy Chengappa
Aug 9, 2015·Brain, Behavior, and Immunity·Chih-Yuan Ko, Yia-Ping Liu
Aug 28, 2007·The Psychiatric Clinics of North America·Deanna L KellyRobert R Conley
Jan 13, 2009·Acta Psychiatrica Scandinavica·J M Meyer, S M Stahl
Dec 12, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task force on Treatment Guidelines for Schizophrenia
Jan 6, 2005·The Annals of Pharmacotherapy·E Kelly Hester, Margaret R Thrower
Mar 3, 2006·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
May 14, 2008·The Australian and New Zealand Journal of Psychiatry·Sanil Rege
Nov 11, 2005·Journal of Psychopharmacology·Chris BusheJohn Pendlebury
Nov 11, 2005·Journal of Psychopharmacology·Chris Bushe, Carol Paton
Apr 17, 2008·Harvard Review of Psychiatry·Lauren ShinNancy Noyes
Apr 28, 2006·Current Opinion in Psychiatry·Maria A Rettenbacher
Sep 22, 2005·Human Psychopharmacology·Ilkka LarmoUNKNOWN Spectrum Study Group
Mar 31, 2006·Behavioural Pharmacology·Mikhail KalinichevDeclan N C Jones
Nov 1, 2012·Human Psychopharmacology·Yinbo Zhang, Guangzhi Dai
Feb 7, 2021·Schizophrenia Bulletin·Dan SiskindWade Marteene